Once-Daily MMX Mesalamine in the Management of Ulcerative colitis

Wojciech Blonski; Anna M. Buchner; Gary R. Lichtenstein

doi:10.4137/CGast.S4276

Clinical Medicine Insights: Gastroenterology (Jan 2011)

Once-Daily MMX Mesalamine in the Management of Ulcerative colitis

Wojciech Blonski,
Anna M. Buchner,
Gary R. Lichtenstein

Affiliations

Wojciech Blonski: Department of Gastroenterology, Medical University, Wroclaw, Poland.
Anna M. Buchner: Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.
Gary R. Lichtenstein: Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.

DOI: https://doi.org/10.4137/CGast.S4276
Journal volume & issue: Vol. 4

Abstract

Read online

Mesalamine (5-ASA) has been the mainstay therapy of mild to moderate active ulcerative colitis both as an induction and maintenance treatment. Multimatrix system (MMX) 5-ASA is a recently developed formulation of 5-ASA allowing for slow and gradual release of 5-ASA throughout the entire colon. This review article discusses the structure, pharmacokinetics, efficacy and safety of this new 5-ASA formulation.

Published in Clinical Medicine Insights: Gastroenterology

ISSN: 1179-5522 (Online)
Publisher: SAGE Publishing
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://journals.sagepub.com/home/cmg

About the journal